Hainan Poly Pharm (300630.SZ): Busulfex injection granted temporary approval by the US FDA.

03/03/2024

GMT Eight

Hainan Poly Pharm (300630.SZ) announced that the company recently received temporary approval from the Food and Drug Administration (FDA) of the United States for the injection of Brivudine. The indication for this drug is the treatment of partial onset seizures in patients aged 1 month and older.

Zhejiang Shuanghuan Driveline (002472.SZ) achieved a net profit of 816 million yuan in 2023, an increase of 40.2% year-on-year.

Zhejiang Shuanghuan Driveline (002472.SZ) plans to spin off its subsidiary Huandong Technology and list it on the Science and Technology Innovation Board of the Shanghai Stock Exchange.

Contact: contact@gmteight.com

Hainan Poly Pharm (300630.SZ): Busulfex injection granted temporary approval by the US FDA.

RECOMMEND

Black sesame (02533) completed the issuance of a total of 53.65 million shares of allocated shares.

SHANGHAI FUDAN (01385) announced its preliminary performance for 2024, with a net profit attributable to the parent of approximately 573 million yuan, a year-on-year decrease of about 20.43%.

SIICENVIRONMENT (00807): Will no longer voluntarily disclose financial performance for the first and third quarters of each financial year.